Doxorubicin

Generic Name
Doxorubicin
Brand Names
Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
Drug Type
Small Molecule
Chemical Formula
C27H29NO11
CAS Number
23214-92-8
Unique Ingredient Identifier
80168379AG
Background

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication

Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions
AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
Associated Therapies
-
Clinical Trials
Related News

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date
2023-11-09
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
680
Registration Number
NCT06124157

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

First Posted Date
2023-11-08
Last Posted Date
2023-11-08
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
24
Registration Number
NCT06121570
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

First Posted Date
2023-11-01
Last Posted Date
2024-12-19
Lead Sponsor
AstraZeneca
Target Recruit Count
1728
Registration Number
NCT06112379
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

First Posted Date
2023-10-24
Last Posted Date
2024-12-06
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
733
Registration Number
NCT06097364
Locations
🇨🇱

Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, Chile

🇮🇱

Hadassah Medical Center, Jerusalem, Israel

🇮🇱

Rabin Medical Center, Petah Tikva, Israel

and more 69 locations

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

First Posted Date
2023-10-19
Last Posted Date
2024-12-12
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
904
Registration Number
NCT06091865
Locations
🇫🇷

Hopital Saint Vincent-de-Paul, Lille, Nord, France

🇰🇷

St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Yeouido St. Marys Hospital, Seoul, Korea, Republic of

and more 139 locations

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

First Posted Date
2023-10-19
Last Posted Date
2024-12-20
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
478
Registration Number
NCT06091254
Locations
🇪🇸

Hospital Clinico Universitario Valencia, Valencia, Spain

🇪🇸

Hospital Universitary and Politecnic La Fe, Valencia, Spain

🇨🇭

Kantonsspital Baden, Baden, Aargau, Switzerland

and more 132 locations

Study of Lurbinectedin in Combination with Doxorubicin Versus Doxorubicin Alone As First-line Treatment in Participants with Metastatic Leiomyosarcoma

Phase 2
Recruiting
Conditions
Leiomyosarcoma
Interventions
Drug: Lurbinectedin
Drug: Doxorubicin
First Posted Date
2023-10-18
Last Posted Date
2024-12-13
Lead Sponsor
PharmaMar
Target Recruit Count
360
Registration Number
NCT06088290
Locations
🇺🇸

Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States

🇫🇷

Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz, Besançon Cedex, Doubs, France

🇮🇹

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas, Rozzano, Milan, Italy

and more 70 locations

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

First Posted Date
2023-09-28
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
3680
Registration Number
NCT06058377
Locations
🇺🇸

Banner University Medical Center - Tucson, Tucson, Arizona, United States

🇺🇸

University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

🇺🇸

Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

and more 406 locations

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-11-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1130
Registration Number
NCT06047080
Locations
🇩🇪

Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany

🇺🇸

Kaiser Permanente Medical Ctr, Vallejo, California, United States

🇺🇸

St. Luke's Hospital, Chesterfield, Missouri, United States

and more 236 locations

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

First Posted Date
2023-09-05
Last Posted Date
2024-07-23
Lead Sponsor
Yonsei University
Target Recruit Count
198
Registration Number
NCT06023862
Locations
🇰🇷

Bundang Seoul National University Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Severance Hospital, Yonsei Health System, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy